Body Dysmorphic Disorder

Body Dysmorphic Disorder (BDD) is an obsessive-compulsive spectrum condition in which a person becomes preoccupied with one or more perceived defects or flaws in physical appearance that are not observable or appear slight to others. DSM-5-TR classifies it under Obsessive-Compulsive and Related Disorders, alongside OCD, hoarding disorder, trichotillomania, and excoriation disorder. The preoccupation causes significant distress and drives repetitive behaviours (mirror checking, grooming, skin picking, reassurance seeking) or mental acts (comparing one's appearance to others). References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Body Dysmorphic Disorder (BDD) is an obsessive-compulsive spectrum condition in which a person becomes preoccupied with one or more perceived defects or flaws in physical appearance that are not observable or appear slight to others. DSM-5-TR classifies it under Obsessive-Compulsive and Related Disorders, alongside OCD, hoarding disorder, trichotillomania, and excoriation disorder. The preoccupation causes significant distress and drives repetitive behaviours (mirror checking, grooming, skin picking, reassurance seeking) or mental acts (comparing one's appearance to others). BDD is severely underdiagnosed: most individuals with BDD present to dermatologists or cosmetic surgeons rather than psychiatrists, and shame prevents disclosure. Approximately 76-80% of individuals with BDD never receive a correct psychiatric diagnosis. The condition typically begins in adolescence (mean onset age ~16), affects men and women at roughly equal rates, and runs a chronic course without treatment. This information is for psychoeducation only.

Preoccupation with perceived appearance flaws focuses most commonly on: skin (acne, scars, wrinkles, colour - ~73%); hair (thinning, excessive body hair, hairline - ~56%); nose (size, shape - ~37%); eyes; teeth; weight/body build; breasts; genitals. Most individuals focus on 5-7 body areas over the course of illness. The flaws are not observable to others, or if a minor physical irregularity exists, the person's concern is grossly disproportionate. Repetitive behaviours: mirror checking (compulsive and time-consuming, though some avoid mirrors entirely); excessive grooming (combing, applying makeup, hair styling for hours); skin picking to "fix" perceived defects (can cause real disfigurement); reassurance seeking about appearance; comparing one's appearance to others (in person, in photos, on social media); frequent clothes changing; touching/measuring the perceived flaw; excessive exercise (especially in muscle dysmorphia); camouflaging (hats, sunglasses, heavy makeup, body positioning, growing a beard to cover jaw/skin). Mental acts: constantly comparing appearance to others; mentally reviewing and analysing appearance; seeking specific angles or lighting to check the flaw. Associated features: ideas or delusions of reference (~60% believe others take special notice of, stare at, or mock their perceived flaw); social avoidance due to shame; housebound behaviour in severe cases (~30%); poor insight or absent insight/delusional beliefs about appearance (~27-60% have delusional conviction that their flaw is real and obvious).

Childhood/adolescent experiences: bullying about appearance (reported by ~60% of BDD patients); teasing; childhood neglect or emotional abuse; sexual abuse. Early experiences of being valued primarily for appearance increase vulnerability. Temperament: high aesthetic sensitivity; perfectionism; neuroticism; introversion; behavioural inhibition. Pre-existing body dissatisfaction and appearance-based self-worth create a cognitive vulnerability. Family history: first-degree relatives of BDD patients have elevated rates of OCD (~7%) and BDD itself (~3-8%). Shared genetic liability with OCD is likely, given their classification in the same diagnostic family. Cultural factors: societies emphasising physical appearance, thinness, muscularity, or specific beauty standards may increase risk. Social media exposure (appearance-filtered images, comparison culture) is associated with body image disturbance, though a direct causal link to BDD has not been established. Dermatological conditions: having a visible skin condition (acne, eczema, psoriasis) during adolescence may trigger BDD in vulnerable individuals, where concern becomes disproportionate and persists after the condition resolves.

Neurobiological: serotonin system dysfunction is central (supported by SSRI treatment response). Dopaminergic dysregulation may contribute, particularly in delusional BDD. Structural MRI shows reduced volume of the orbitofrontal cortex and anterior cingulate cortex. Functional neuroimaging reveals abnormal visual processing: BDD patients over-activate detail-oriented processing streams (left hemisphere, lateral occipital regions) and under-activate global/holistic processing networks when viewing faces - including their own. This mirrors the subjective experience of being "zoomed in" on perceived flaws while missing the overall picture. Cognitive model: selective attention to perceived flaws, biased interpretation of ambiguous social cues as appearance-related, overestimation of the importance of appearance to self-worth, and distorted mental imagery of one's own appearance (which may differ significantly from what the mirror or camera shows). Genetic: twin studies suggest moderate heritability, though precise estimates for BDD alone are limited. Shared genetic architecture with OCD is supported by family studies. No specific BDD susceptibility genes have been identified. Psychological: perfectionism, negative appearance-related core beliefs ("I am defective/ugly"), and maladaptive schemas about unlovability or social rejection develop from early adverse experiences and maintain the disorder through safety behaviours and avoidance.

General population prevalence: ~1.7-2.4% (community surveys). In clinical settings: ~9-15% of dermatology patients; ~7-8% of cosmetic surgery patients; ~8-37% of patients with OCD. Point prevalence among US adults is ~2.4% (women ~2.5%, men ~2.2%). Age of onset: typically 12-17 years (mean ~16). Childhood onset occurs but is less well studied. BDD symptoms usually begin gradually and worsen over adolescence.

Sex distribution: approximately equal in community samples, though presentation differs. Women more commonly focus on skin, weight, hips, breasts, and legs; men more commonly focus on muscularity, hair thinning, and genitals. The muscle dysmorphia subtype affects predominantly men (~80%). Comorbidity is the rule: major depressive disorder (~75% lifetime); social anxiety disorder (~37%); OCD (~30-40%); substance use disorders (~30%, often using substances to cope with distress or to facilitate social situations); eating disorders (~9-32%). Suicidality is alarmingly high: ~80% report lifetime suicidal ideation; ~24-28% have attempted suicide; completed suicide rate estimated at ~0.3% per year, roughly 45 times the general population rate.

Visual processing abnormalities are the most distinctive finding. When viewing faces (their own or others'), BDD patients show hyperactivation of the left inferior frontal gyrus and left lateral occipital complex - regions involved in detailed, feature-by-feature processing. They show relative hypoactivation of right hemisphere holistic processing networks. In forced-choice perception tasks, BDD patients preferentially encode fine details over global form, even for non-face stimuli. This suggests a general perceptual bias, not limited to appearance. fMRI studies during symptom provocation (viewing one's own face) show increased activation in the orbitofrontal cortex, caudate, and amygdala - overlapping with the OCD circuit. The orbitofrontal-striatal-thalamic loop is implicated in the repetitive, compulsive nature of BDD behaviours. Serotonin: the consistent response to SRIs (and lack of response to non-serotonergic antidepressants) implies serotonergic dysfunction. Whether this is primary or secondary to corticostriatal circuit abnormalities is unclear. White matter integrity: DTI studies show reduced fractional anisotropy in tracts connecting visual processing areas with frontal regulatory regions, suggesting disrupted communication between perception and top-down control. Body size estimation studies show that BDD patients have distorted perception of their own face/body dimensions, overestimating the prominence of areas of concern. This is not simply a cognitive distortion - it appears to involve altered perceptual encoding.

BDD is typically missed unless clinicians ask directly. The BDD Questionnaire (BDDQ) is a brief self-report screening tool (sensitivity ~100%, specificity ~89% in psychiatric settings). Direct questions: "Do you spend a lot of time worrying about your appearance?" "Is there any part of your body you're particularly unhappy about?" "Does this concern take up a lot of your day or get in the way of your life?" Assess: specific body areas of concern; time spent on appearance-related thoughts per day (BDD patients average 3-8 hours); types and frequency of repetitive behaviours; degree of avoidance (work, school, social); level of insight (good, poor, absent/delusional); suicidal ideation and history of attempts (mandatory - BDD suicide risk is very high). The Yale-Brown Obsessive Compulsive Scale modified for BDD (BDD-YBOCS) is the gold-standard clinician-rated severity measure (score 0-48; >=20 = moderate; >=30 = severe). Physical exam: look for skin damage from picking, hair loss from pulling, signs of excessive cosmetic procedures. Document any actual physical abnormalities to calibrate the degree of preoccupation distortion. Rule out dermatological conditions that may warrant treatment.

DSM-5-TR criteria: (A) Preoccupation with one or more perceived defects or flaws in physical appearance that are not observable or appear slight to others. (B) At some point during the course of the disorder, the individual has performed repetitive behaviours (mirror checking, excessive grooming, skin picking, reassurance seeking) or mental acts (comparing appearance with that of others) in response to the appearance concerns. (C) The preoccupation causes clinically significant distress or impairment in social, occupational, or other areas of functioning. (D) The appearance preoccupation is not better explained by concerns with body fat or weight in an individual whose symptoms meet diagnostic criteria for an eating disorder. Specifier: with muscle dysmorphia - the individual is preoccupied with the idea that their body build is too small or insufficiently muscular (almost exclusively male; associated with compulsive weightlifting, restrictive dieting, and anabolic steroid use). Insight specifier: with good or fair insight; with poor insight; with absent insight/delusional beliefs. Approximately 27-60% of BDD patients have poor or absent insight, believing their perceived defect is genuinely apparent to others. DSM-5-TR no longer requires a separate diagnosis of delusional disorder, somatic type, for delusional BDD - it is classified as BDD with absent insight. ICD-11 code: 6B21 (Body dysmorphic disorder), classified under Obsessive-Compulsive or Related Disorders.

The BDDQ (BDD Questionnaire) screens effectively in clinical settings. The BDD-YBOCS (12-item clinician-rated scale) measures severity across: time occupied by thoughts, interference, distress, resistance, and control (for both obsessions and compulsive behaviours). Scores: 0-7 subclinical; 8-15 mild; 16-23 moderate; 24-31 moderate-severe; 32-48 severe. The Brown Assessment of Beliefs Scale (BABS) measures insight/delusionality. The Appearance Anxiety Inventory (AAI) assesses avoidance and safety behaviours related to BDD. The Body Image Disturbance Questionnaire (BIDQ) and Dysmorphic Concern Questionnaire (DCQ) are additional screening tools.

Structured diagnostic interview: the SCID-5 BDD module or the Body Dysmorphic Disorder Diagnostic Module (BDD-DM). Assess all comorbid conditions: depression (PHQ-9), social anxiety (LSAS), OCD (Y-BOCS), suicidality (C-SSRS), substance use, eating disorders. Functional assessment: employment status, relationship functioning, ability to leave the house, time lost to BDD behaviours. No laboratory tests or neuroimaging are indicated for diagnosis. However, if cosmetic procedures are being sought, psychiatric evaluation before surgery is strongly recommended - BDD patients are almost invariably dissatisfied with cosmetic outcomes.

OCD: in OCD, obsessions can involve any theme (contamination, harm, symmetry); BDD obsessions are specifically about appearance. If both appearance and non-appearance obsessions are present, both diagnoses can be given. Eating disorders: anorexia nervosa involves preoccupation with body weight and fatness specifically, meeting eating disorder criteria; if weight/body fat is the sole concern, AN is diagnosed. If other appearance concerns co-occur, both diagnoses may be warranted. Social anxiety disorder: avoidance in SAD stems from fear of negative evaluation more broadly; in BDD, avoidance is specifically about the perceived flaw being noticed. The two co-occur in ~37% of cases. Major depressive disorder: MDD produces negative self-image broadly, but not the specific, persistent preoccupation with a particular physical feature and associated repetitive behaviours. MDD co-occurs with BDD in ~75% of cases and usually develops secondary to BDD. Normal appearance dissatisfaction: most people dislike something about their appearance; BDD differs by the intensity of preoccupation (hours daily), the degree of distress, and the functional impairment. Illness anxiety disorder (hypochondria): preoccupation centres on having or developing a serious disease, not on appearance. Delusional disorder, somatic type: DSM-5-TR classifies delusional BDD as BDD with absent insight, eliminating the need for this separate diagnosis. Trichotillomania: repetitive hair pulling is ego-dystonic and driven by urge rather than appearance concern; however, hair pulling in BDD is motivated by trying to "fix" perceived flaws.

Treatment of Body Dysmorphic Disorder (BDD) involves CBT specifically adapted for BDD and pharmacotherapy with serotonin reuptake inhibitors. Psychotherapy: CBT for BDD is the first-line psychotherapy and includes exposure and response prevention (ERP) targeting BDD-specific rituals (mirror checking, reassurance seeking, skin picking, camouflaging), cognitive restructuring of distorted appearance-related beliefs, perceptual retraining to shift from selective detail-focused attention to perceived flaws toward a more global view of appearance, and behavioural experiments to test catastrophic predictions (e.g., going out without camouflage to test whether people react negatively). Treatment typically involves 12-22 sessions. Response rates for CBT are ~50-80% in clinical trials. The Wilhelm/Phillips/Steketee CBT model is the most well-validated protocol. Group CBT has also shown effectiveness. Internet-delivered CBT (BDD-NET) produced significant symptom reduction in a Swedish RCT. Pharmacotherapy: SSRIs at higher doses than typically used for depression are the first-line medication treatment. Evidence exists for fluoxetine (40-80mg), fluvoxamine (150-300mg), escitalopram (20-40mg), and sertraline (150-400mg,

above standard dosing range). Adequate trial duration is 12-16 weeks at maximum tolerated dose before considering non-response. Response rates to SRIs are ~50-70%. Clomipramine (75-250mg) is an alternative for SSRI non-responders; monitoring ECG and drug levels is required. Augmentation with low-dose aripiprazole (2-15mg) or pimozide may benefit patients with delusional beliefs about their appearance, though evidence is limited. Combined treatment with CBT and an SSRI is often recommended, especially for moderate-to-severe cases. If one modality alone produces insufficient response, adding the other is the standard next step. Cosmetic procedures (surgery, dermatological treatments) are generally ineffective for BDD and may worsen symptoms. Studies report that 81-91% of BDD patients are dissatisfied with cosmetic outcomes, and preoccupation typically shifts to the treated area or to a new body part. Cosmetic surgeons who identify BDD should refer to psychiatry rather than operate. Patient education about BDD as a treatable psychiatric condition rather than a physical appearance problem is important to engage patients who may resist psychiatric referral.

BDD runs a chronic course without treatment. The mean illness duration before first treatment is ~10-15 years. Prospective studies show a full remission probability of only ~20% over 1 year and ~9% annual remission rate without treatment. With CBT: ~50-80% of patients show clinically significant improvement; gains are maintained at 1-2 year follow-up in most responders. With SRIs: ~50-70% respond; relapse rates are ~50-70% within months of discontinuation, supporting long-term maintenance pharmacotherapy. Predictors of poor outcome: longer illness duration before treatment; comorbid personality disorder; delusional conviction about the flaw; more severe baseline symptoms; history of cosmetic surgery for BDD concerns. Predictors of better outcome: younger age at treatment onset; shorter duration; good insight; strong therapeutic alliance; treatment completion. Suicidal behaviour remains the most serious prognostic concern: ~80% lifetime suicidal ideation; ~24-28% lifetime suicide attempts. BDD patients require ongoing suicide risk monitoring, especially during treatment initiation and non-response periods.

Suicide and self-harm: the most dangerous complication; BDD has one of the highest suicide rates among psychiatric disorders. Social isolation: ~30% become housebound for extended periods; many drop out of school or leave employment. Unnecessary cosmetic procedures: BDD patients undergo repeated surgeries (average 2-3 procedures), often travelling to multiple providers, with consistently poor subjective outcomes and risk of physical disfigurement. Skin damage: compulsive picking causes wounds, scars, and infections that create real disfigurement - the very outcome the patient feared.

Financial burden: cosmetic procedures, excessive grooming products, and lost productivity create significant costs. Substance use: ~30% develop substance use disorders, often using alcohol or stimulants to manage social anxiety or enhance confidence about appearance. Iatrogenic harm: dermatologists and cosmetic surgeons who treat BDD symptoms without recognising the psychiatric condition may reinforce the belief that the problem is physical. Relationship dysfunction: BDD-related avoidance, reassurance seeking, and preoccupation strain intimate relationships.

No proven primary prevention exists. Early detection is the best secondary prevention strategy. Dermatologists, cosmetic surgeons, and primary care providers should screen for BDD when patients present with appearance concerns disproportionate to any observable physical issue, request repeated or excessive procedures, or express extreme distress about minor features. Key messages for patients: BDD is a brain-based condition, not vanity. The way you see yourself is distorted by the disorder - others genuinely do not see what you see. Cosmetic surgery will not fix BDD and usually makes it worse. Effective treatments exist: CBT and SRIs produce meaningful improvement in the majority of patients. The shame and secrecy are part of the disorder - telling your clinician about appearance concerns is the first step. Suicidal thoughts require immediate help. For families: BDD is not about fishing for compliments. Reassurance ("you look fine") does not help and can reinforce the compulsive cycle. Accommodation (allowing avoidance, participating in checking rituals) maintains the disorder. Supporting treatment engagement and reducing accommodation are the most helpful actions.

1891: Enrico Morselli, an Italian psychiatrist, described "dysmorphophobia" - an intense fear of being deformed. He observed patients whose subjective perception of ugliness was vastly disproportionate to their actual appearance. 1903: Pierre Janet described "l'obsession de la honte du corps" (the obsession of shame of the body). For most of the 20th century, BDD was considered rare and psychodynamically interpreted as displaced sexual anxiety. 1980: DSM-III included "dysmorphophobia" as an atypical somatoform disorder - not a standalone diagnosis. 1987: DSM-III-R introduced Body Dysmorphic Disorder as a distinct somatoform disorder. 1997: Katharine Phillips published the first major clinical monograph on BDD, transforming understanding and treatment. 2013: DSM-5 reclassified BDD from Somatoform Disorders to Obsessive-Compulsive and Related Disorders, reflecting its phenomenological, neurobiological, and treatment-response similarities to OCD. The muscle dysmorphia specifier was also added.

BDD is shaped by cultural beauty standards. Western media idealise thinness, symmetry, and youth; K-beauty culture emphasises flawless skin and specific facial proportions. Social media and filtered selfies create unrealistic appearance benchmarks. "Snapchat dysmorphia" describes the phenomenon of patients presenting to dermatologists or surgeons requesting to look like their filtered photos. Despite its prevalence, BDD is rarely depicted accurately in media. It is often trivialised as vanity or confused with narcissism. In reality, BDD patients have extremely low self-esteem and feel repulsive - the opposite of narcissistic

self-admiration. Muscle dysmorphia in men is increasingly recognised, partly driven by social media fitness culture, superhero body standards, and easy access to anabolic steroids. Affected individuals may spend 3-5 hours daily at the gym, follow extremely rigid diets, and use potentially dangerous supplements or steroids despite already having above-average muscularity. BDD is significantly underdiagnosed across all cultures. Patients typically wait 10-15 years before receiving a correct diagnosis. Shame about being seen as vain or superficial prevents disclosure. Clinicians in primary care, dermatology, and cosmetic surgery settings are in the best position to detect BDD but rarely screen for it.

Neuroimaging: fMRI studies continue to clarify the detail-biased visual processing that distinguishes BDD from healthy controls and from other psychiatric conditions. Connectivity analyses explore disrupted communication between occipital visual areas and frontal regulatory regions. Transcranial magnetic stimulation (TMS) targeting the right temporoparietal junction (involved in holistic face processing) is under investigation as a treatment. Pharmacotherapy: studies are exploring optimal SSRI dosing for BDD (higher than depression doses but with limited dose-finding data); glutamate modulators (memantine, N-acetylcysteine) as SRI augmentation strategies; psilocybin-assisted therapy (early case reports suggest reduced appearance preoccupation); and d-cycloserine as a CBT enhancer (augmenting exposure learning, as studied in OCD and social anxiety). Digital therapeutics: BDD-NET (internet-delivered CBT) showed significant reduction in BDD-YBOCS scores in an RCT. Smartphone apps delivering ERP exercises and perceptual retraining are in development. Virtual reality exposure therapy - simulating social situations while reducing camouflaging - is being piloted. Understanding muscle dysmorphia: research is clarifying its relationship to both BDD and eating disorders, prevalence among athletes and gym-goers (~22% of male weightlifters meet criteria), and risk factors including anabolic steroid use.

APA. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR). APA Publishing. Sadock BJ, Sadock VA, Ruiz P. (Eds.). (2024). Kaplan & Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls [Internet]. Body Dysmorphic Disorder. NCBI Bookshelf. StatPearls Publishing. WHO. (2022). ICD-11 for Mortality and Morbidity Statistics. Geneva: World Health Organization. Phillips KA. (2005). The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. Oxford University Press.

StatPearls: https://www.ncbi.nlm.nih.gov/books/NBK555901/ BDD Foundation: https://bddfoundation.org IOCDF BDD page: https://iocdf.org/about-ocd/related-disorders/body-dysmorphic-disorder/ NIMH: https://www.nimh.nih.gov WHO ICD-11 code 6B21: https://icd.who.int Crisis: 988 (US Suicide & Crisis Lifeline); Text HOME to 741741 (Crisis Text Line) Note: Educational only. Not a substitute for professional care.